Trial · NCT07173127
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the mean value of normalized activated protein C resistance (nAPCsr) at 3 months of treatment with Ryeqo | At baseline and after 3 months of treatment | Blood dosage of normalized activated protein C resistance (nAPCsr) |
| Secondary | Mean change from baseline to 3 months of treament in the value of sexual hormone-binding globulin (SHBG) | At baseline and after 3 months of treatment | Mean value of SHBG as expressed in nmol/l units |
| Secondary | Mean change from baseline to 3 months of treament in the value of normalized thrombomodulin sensitivity ratios (nTMSR) | At baseline and after 3 months of treatment | Mean value of nTMSR as expressed as ratio |
| Secondary | Mean change from baseline to 3 months of treament in the value of D-Dimers | At baseline and after 3 months of treatment | Mean value of D-dimers as expressed with ng/ml units |
| Secondary | Mean change from baseline to 3 months of treament in the value of thrombin generation markers | At baseline and after 3 months of treatment | Mean value of thrombin generation markers, such as : thrombin generation markers * endogenous thrombin potential (ETP), expressed in nMxmin * peak value, expressed in nM * time to peak, expressed in min * lag time, expressed in min |
| Secondary | Mean change from baseline to 3 months of treament in the value of antithrombin activity | At baseline and after 3 months of treatment | Mean change in antithrombin activity, expressed as a percentage |
| Secondary | Mean change from baseline to 3 months of treament in the value of Tissue factor pathway inhibitor (TFPI) | At baseline and after 3 months of treatment | Mean change in the value of TFPI, as expressed in ng/ml |
| Secondary | Mean change from baseline to 3 months of treament in the value of fibrinogen | At baseline and after 3 months of treatment | Mean change in the value of fibrinogen, as expressed in g/l |
| Secondary | Mean change from baseline to 3 months of treament in the value of free protein S | At baseline and after 3 months of treatment | Mean change in the value of free protein S, expressed as a percentage |
| Secondary | Mean change from baseline to 3 months of treament in the value of factor VIII concentration | At baseline and after 3 months of treatment | Mean change in the value of factor VIII concentration, expressed as a percentage |
| Secondary | Mean change from baseline to 3 months of treament in the value of thrombin-antithrombin-komplex (TAT) | At baseline and after 3 months of treatment | Mean change in the value of TAT concentration, expressed in microgr/l |
| Other | Mean days of headache at 3 months of treatment | At 3 months of treatment | Number of participants having headache and, if so, mean numberof days spent experiencing headache |
| Other | Mean number of days with pelvic pain at 3 months of treatment | At 3 months of treatment | Number of participants experiencing pelvic pain and, if so, mean number of days spent with pelvic pain |
| Other | Mean difference from baseline on the Higham scale of bleeding at 3 months of treatment | At baseline and after 3 months of treatment | There is no minimum or maximum value. A score inferior to 100 indicates normal flow, a score of 100 or more suggests heavy bleeding, and a score of 150 or more signifies heavy bleeding |
| Other | Mean number of days of experiencing hot flush | After 3 months of treatment | Number of participants experiecing hot flush and, if so, mean number of days spent experiecing hot flush |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07173127/registered